共 50 条
- [21] Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerCLINICAL CANCER RESEARCH, 2024, 30 (04) : 754 - 766Jhaveri, Komal L.Bellet, MeritxellTurner, Nicholas C.Loi, ShereneBardia, AdityaBoni, ValentinaSohn, JoohyukNeilan, Tomas G.Villanueva-Vazquez, RafaelKabos, PeterGarcia-Estevez, LauraLopez-Miranda, ElenaPerez-Fidalgo, J. AlejandroPerez-Garcia, Jose M.Yu, JiajieFredrickson, JillMoore, Heather M.Chang, Ching-WeiBond, John W.Eng-Wong, JenniferGates, Mary R.Lim, Elgene
- [22] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerFUTURE ONCOLOGY, 2023, : 727 - 736Kahraman, SedaErul, EnesSeyyar, MustafaGumusay, OzgeBayram, ErtugrulDemirel, Burcin CakanAcar, OmerAksoy, SercanBaytemur, Naziyet KoseSahin, ElifCabuk, DevrimBasaran, GulPaydas, SemraYaren, ArzuGuven, Deniz CanErdogan, Atike PinarDemirci, UmutYasar, AlperBayoglu, Ibrahim VedatHizal, MutluGulbagci, BurcuPaksoy, NailDavarci, Sena EceYilmaz, FundaDogan, OzlemOrhan, Sibel OyucuKayikcioglu, ErkanAytac, AliKeskinkilic, MerveMocan, Eda EylemerUnal, Olcun UmitAydin, EsraYucel, HakanIsik, DenizEren, OnderUluc, Basak OyanOzcelik, MelikeHacibekiroglu, IlhanAydiner, AdnanDemir, HacerOksuzoglu, BernaCilbir, EbruCubukcu, ErdemCetin, BulentOktay, EsinErol, CihanOkutur, Sadi KeremYildirim, NilgunAlkan, AliSelcukbiricik, Fatih
- [23] Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET TrialJOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 178 - +Johnston, StephenPuhalla, ShannonWheatley, DuncanRing, AlistairBarry, PeterHolcombe, ChrisBoileau, Jean FrancoisProvencher, LouiseRobidoux, AndreRimawi, MothaffarMcIntosh, Stuart A.Shalaby, IbrahimStein, Robert C.Thirlwell, MichaelDolling, DavidMorden, JamesSnowdon, ClairePerry, SophieCornman, ChesterBatten, Leona M.Jeffs, Lisa K.Dodson, AndrewMartins, VeraModi, ArjunOsborne, C. KentPogue-Geile, Katherine L.Cheang, Maggie Chon U.Wolmark, NormanJulian, Thomas B.Fisher, KateMacKenzie, MaireadWilcox, MaggieBartlett, Cynthia HuangKoehler, MariaDowsett, MitchBliss, Judith M.Jacobs, Samuel A.
- [24] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRANVALUE IN HEALTH, 2019, 22 : S472 - S472Taheri, S.Majd, Karimi Z.Rezaei, S.Yousefi, N.Peiravian, F.
- [25] Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL studyEUROPEAN JOURNAL OF CANCER, 2022, 168 : 12 - 24Martin, MiguelZielinski, ChristophRuiz-Borrego, ManuelCarrasco, EvaCiruelos, Eva M.Munoz, MontserratBermejo, BegonaMargeli, MireiaCsoszi, TiborAnton, AntonioTurner, NicholasCasas, Maria, IMorales, SerafinAlba, EmilioCalvo, LourdesDe La Haba-Rodriguez, JuanRamos, ManuelMurillo, LauraSantaballa, AnaAlonso-Romero, Jose L.Sanchez-Rovira, PedroCorsaro, MassimoHuang, XinThallinger, ChristianeKahan, ZsuzsannaGil-Gil, Miguel
- [26] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Martin, MiguelLim, ElgeneMac Gregor, Mariana ChavezShivhare, MaheshRoss, GrahamPatre, MonikaRoncoroni, LauraLouka, MariaSohn, Joohyuk
- [27] Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)CANCERS, 2024, 16 (18)Chae, HeejungSim, Sung HoonKwon, YoungmiLee, Eun-GyeongHan, Jai HongJung, So-YounLee, SeeyounKang, Han-SungKim, Yeon-JooKim, Tae HyunLee, Keun Seok
- [28] Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerCLINICAL BREAST CANCER, 2018, 18 (06) : E1239 - E1245Stearns, VeredBrufsky, Adam M.Verma, ShailendraCotter, Matthew J.Lu, Dongrui R.Dequen, FlorenceJoy, Anil Abraham
- [29] Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Moore, Heather M.Boni, ValentinaBellet, MeritxellDe Las Heras, Begona BermejoCortes, Maria GionOakman, CatherineSchmid, PeterTrinh, Xuan BichWheatley, DuncanJhaveri, Komal L.Kabos, PeterLim, ElgeneVelu, ThierryMetcalfe, CiaraGates, Mary R.Chang, Ching-WeiBond, JohnGoldstein, Leonard D.Lauchle, Jennifer O'HaraBardia, Aditya
- [30] An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerCLINICAL CANCER RESEARCH, 2023, 29 (15) : 2781 - 2790Chandarlapaty, SaratDickler, Maura N.Fidalgo, Jose Alejandro PerezVillanueva-Vazquez, RafaelGiltnane, JenniferGates, MaryChang, Ching-WeiCheeti, SravanthiFredrickson, JillWang, XiaojingCollier, AnnMoore, Heather M.Metcalfe, CiaraLauchle, JenniferHumke, Eric W.Bardia, Aditya